PHAS · Phasebio Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Revenue | $10.83M | $320.0K | $2.36M | $668.0K |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| R&D | $102.11M | $72.09M | $30.91M | $6.21M |
| SG&A | $16.09M | $13.09M | $11.19M | $2.33M |
| Total Operating Expenses | $118.19M | $85.18M | $42.10M | $8.54M |
| D&A | $1.79M | $508.0K | $174.0K | $96.0K |
| Operating Income | ($107.36M) | ($84.86M) | ($39.74M) | ($8.54M) |
| Interest Expense | $947.0K | $1.45M | $1.08M | $2.72M |
| Income Tax | $1.60M | $0 | $0 | $0 |
| Net Income | ($131.07M) | ($98.56M) | ($39.25M) | ($10.25M) |
| EPS - Basic | ($3.39) | - | - | - |
| EPS - Diluted | ($3.39) | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Cash & Equivalents | $41.80M | $28.12M | $74.03M | $61.03M |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | $12.57M | $3.67M | $2.92M | $1.81M |
| Current Assets | $48.78M | $40.15M | $78.82M | $62.63M |
| Total Assets | $60.54M | $50.36M | $82.49M | $63.03M |
| Current Liabilities | $27.88M | $14.96M | $8.48M | $4.58M |
| Long-term Debt | $1.36M | $6.77M | $12.33M | $7.50M |
| Total Liabilities | $153.57M | $75.56M | $22.52M | $12.10M |
| Stockholders' Equity | ($93.03M) | ($25.20M) | $59.98M | ($87.18M) |
| Retained Earnings | ($391.79M) | ($260.72M) | ($162.16M) | ($122.91M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Operating Cash Flow | ($47.42M) | ($59.96M) | ($39.59M) | ($8.26M) |
| Investing Cash Flow | ($2.68M) | ($1.41M) | ($960.0K) | ($216.0K) |
| Financing Cash Flow | $63.77M | $15.47M | $53.53M | $18.17M |
| CapEx | $2.68M | $1.31M | $960.0K | $216.0K |
| Free Cash Flow | ($50.09M) | ($61.27M) | ($40.55M) | ($8.47M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | - | - | - | - |
| Operating margin | -991.2% | -26517.5% | -1683.0% | -1278.1% |
| EBITDA margin | -974.7% | -26358.7% | -1675.6% | -1263.8% |
| Net margin | -1210.1% | -30801.6% | -1662.3% | -1534.0% |
| Free cash flow margin | -462.5% | -19146.6% | -1717.7% | -1268.7% |
| FCF / Net income | 0.38 | 0.62 | 1.03 | 0.83 |
| R&D / Revenue | 942.7% | 22527.5% | 1309.2% | 929.6% |
| SG&A / Revenue | 148.5% | 4090.0% | 473.8% | 348.5% |
| Effective tax rate | - | - | - | - |
| Return on assets | -216.5% | -195.7% | -47.6% | -16.3% |
| Return on equity | 140.9% | 391.1% | -65.4% | 11.8% |
| Return on invested capital | - | - | -43.4% | - |
| Liquidity | ||||
| Current ratio | 1.75 | 2.68 | 9.30 | 13.68 |
| Quick ratio | 1.75 | 2.68 | 9.30 | 13.68 |
| Cash ratio | 1.50 | 1.88 | 8.73 | 13.33 |
| Leverage | ||||
| Debt / Equity | -0.01 | -0.27 | 0.21 | -0.09 |
| Debt / Assets | 0.02 | 0.13 | 0.15 | 0.12 |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | -113.4x | -58.7x | -36.9x | -3.1x |
| Equity multiplier | -0.65 | -2.00 | 1.38 | -0.72 |
| Liabilities / Assets | 2.54 | 1.50 | 0.27 | 0.19 |
| Efficiency | ||||
| Asset turnover | 0.18 | 0.01 | 0.03 | 0.01 |
| Inventory turnover | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days inventory outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Cash conversion cycle | - | - | - | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | 3284.7% | -86.4% | 253.4% | - |
| Revenue CAGR (3y) | 153.1% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - |
| Operating income growth (YoY) | -26.5% | -113.5% | -365.4% | - |
| Net income growth (YoY) | -33.0% | -151.1% | -283.0% | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | 18.2% | -51.1% | -378.5% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | -269.2% | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$32.46M totalGrant$10.83M · 33.4%
Sublicense Revenue$10.80M · 33.3%
License$10.22M · 31.5%
Development And Regulatory Services$608.0K · 1.9%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-10.82
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PhaseBio Pharmaceuticals Inc against the 5 most active filers in the same SIC group.